Also known as mod-grf(1–29), cjc-1295 without dac, tetrasubstituted grf(1–29) · Wikipedia
CJC-1295 without DAC, also called Mod-GRF(1-29) or tetrasubstituted GRF(1-29), is a short-acting growth hormone-releasing hormone analog built from the first 29 amino acids of native human GHRH with four amino-acid substitutions that resist DPP-IV cleavage. Unlike the long-acting CJC-1295 with DAC, it lacks the maleimido-propionyl albumin-binding linker, so it has a plasma half-life on the order of 30 minutes and produces a discrete pulsatile GH release rather than sustained elevation. It is most often researched as a GHRH partner for ghrelin-mimetic GHRPs (ipamorelin, GHRP-2). It is not FDA-approved and is sold only as a research chemical.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
CJC-1295 without DAC is a tetrasubstituted GHRH(1-29) analog with D-Ala2, Gln8, Ala15, and Leu27 substitutions that confer resistance to dipeptidyl peptidase-IV and trypsin-like proteolysis, extending intrinsic activity beyond native sermorelin. It binds the GHRH receptor (GHRHR), a class-B G-protein coupled receptor on anterior pituitary somatotrophs, raising cAMP and triggering pulsatile endogenous GH release while preserving negative feedback by somatostatin and IGF-1 (https://pubmed.
Pharmacokinetic properties
Half-life
~30 minutes subcutaneous
Routes
subcutaneous
Bioavailability
Short-acting; multiple daily injections (2-3x) typically used to mimic natural GH pulses. Often co-administered with a GHRP for synergy.
Amino-acid sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg (mod GRF 1-29)
Use & research dosing
No FDA-approved dose. In self-experimentation protocols Mod-GRF(1-29) is commonly reported at 100 mcg subcutaneous per injection, 1-3 times daily, typically pre-bed and/or 30-60 minutes pre-workout, often paired 1:1 with a ghrelin agonist such as ipamorelin (100 mcg). Some protocols cycle in 8-12 week blocks with breaks. Research framing only; no validated efficacy or safety threshold exists outside of small GHRH-analog pharmacology studies.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Frequently confused with CJC-1295 with DAC despite radically different pharmacokinetics. The 'no DAC' form is favored in GHRH plus GHRP blends because its short half-life mimics physiologic GH pulsatility rather than the multi-day exposure produced by the DAC version, which has been associated with sustained IGF-1 elevation. Most published clinical pharmacology data describe the DAC compound; the no-DAC tetrasubstituted GRF(1-29) is supported by mechanistic and preclinical work rather than dedicated human trials.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
medium
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.